Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A nationwide screening program from the iStopMM study performed in Iceland to detect smoldering multiple myeloma reported a prevalence of 0.5% in individuals over 40 years of age, with increasing risks with age and in males.
A study prospectively evaluating a stratified approach to selecting treatment heralds a new era of precision medicine for type 2 diabetes, which should incorporate ongoing discovery, social determinants of health and healthcare transformation.
Data sharing enhances the value of medical research and builds trust in clinical trials, but more biomedical researchers need to be trained in these approaches, which include meta-research, data science and ethical, legal and social issues.
The combination of anti-PD-1 treatment with cisplatin and 5-fluorouracil in patients with previously untreated, PD-L1-positive esophageal squamous cell carcinoma improved progression-free survival and overall survival.
Whole-exome sequencing analyses in a cohort of 1,030 patients with premature ovarian insufficiency identify new likely pathogenic variants and reveal distinct genetic architectures between primary and secondary amenorrhea.
High-dose ipilimumab plus nivolumab in locoregionally advanced urothelial cancer led to a higher pathological complete response rate than low-dose ipilimumab in cohort 2. Presurgical absence of plasma (but not urinary) circulating tumor DNA correlated with clinical outcome.
Effectiveness of one subcutaneous dose of MVA-BN, the smallpox and mpox vaccine, was estimated to be 86% in a cohort of vaccine-eligible males in Israel, supporting its use to curtail the outbreak of mpox virus.
Analysis of a longitudinal cohort revealed that only 72% of Chinese adults aged over 60 years received booster COVID-19 vaccination by July 2022, with contraindications, advanced age and living with chronic conditions being the main determinants of vaccine hesitancy in this population.
In a phase I trial, the combination of dabrafenib, trametinib and spartalizumab uncovers the crosstalk between the MAPK pathway and the immune system, which offers a promising new strategy to improve clinical outcomes.
Tumor mutation burden is an imperfect predictor of response to immunotherapies. Mutations in regions of the genome unlikely to undergo loss during tumor evolution constitute a persistent tumor mutation burden that may drive sustained immunological tumor control in the context of cancer immunotherapy.
Despite concerns that bariatric surgery may increase patients’ risk of esophageal or gastric cancers, a large retrospective study offers reassurance that this is not the case.
The drug-scheduling system, particularly the approach to rescheduling, should be reformed to ensure all beneficial medicines, including marijuana and psilocybin, are available to scientists and patients.
A large study finds that offering cash for vaccination does not have unintended negative consequences — providing much-needed data and alleviating some longstanding concerns.
A smartphone-based system, designed to induce a steady gaze in children using cartoon-like video stimuli, can identify visually impaired children across a wide range of ophthalmic disorders, based on analysis of gazing behaviors and facial features.
Patients with BRAFV600E-mutated colorectal cancer have encouraging overall response rates to inhibition of PD-1, BRAF and MEK, with translational analyses suggesting that induction of tumor-intrinsic programs and immune programs contributes to improved outcomes via MAPK inhibition.
Genomic analyses in large cohorts of patients with cancer identify a new measure of tumor mutational burden, based on genomic regions that are unlikely to undergo loss, that is associated with therapeutic response to immunotherapy.
The US Food and Drug Administration should address health misinformation through existing and new regulatory approaches, including modernizing product labeling, investing in infodemic surveillance and addressing the roles of the internet and social media.
Nature Medicine explores the latest translational and clinical research news, with data from an ongoing clinical trial of mosunetuzumabin relapsed or refractory follicular lymphoma.
